Startup profile · funding coverage
Delix Therapeutics funding, valuation and investors
Clinical-stage neuroscience biotech developing non-hallucinogenic neuroplastogen medicines.
Verified company research · funding, investors and latest developments
Keep track of Delix Therapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series C
$100M · November 9, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$100M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · Bedford, Massachusetts, United States
Investors in latest funding
Lead: Johnson & Johnson Innovation – JJDC , SV Health Investors' Dementia Discovery Fund
Other: RA Capital Management , UC Investments
Overview
Delix Therapeutics develops orally available neuroplastogens intended to improve neuroplasticity while avoiding the hallucinogenic effects of conventional psychedelics. On November 9, 2026 Delix announced a $100 million Series C co-led by Johnson & Johnson Innovation–JJDC and SV Health Investors' Dementia Discovery Fund.
The company said proceeds would support a planned Phase IIb major-depressive-disorder trial of zalsupindole and additional research. Reported Phase Ib signals are early-stage company data, not completed pivotal efficacy evidence. Source: https://delixtherapeutics.com/news/delix-closes-100-million-series-c-financing/
Why Delix Therapeutics is interesting
Its $100M November 2026 Series C led by strategic and specialist investors funds planned Phase IIb work; clinical proof of concept is the main value milestone.
Product & use cases
Zalsupindole and a broader portfolio of experimental neuroplastogen medicines targeting psychiatric and neurological disease.
Funding history (newest first)
Series C
2026-11-09 $100M- Johnson & Johnson Innovation – JJDC (lead)
- SV Health Investors' Dementia Discovery Fund (lead)
- RA Capital Management (participant)
- UC Investments (participant)
Competitive landscape
Edge: Distinct therapeutic mechanism and emerging Phase I human data; investors must verify reproducibility in controlled later trials.
Clinical strategy faces safety, placebo response, reproducibility and competition from existing antidepressant treatments. The announced 2027 trial plan is prospective.
Industries
Market / IPO context
Editorial / static context — not a live quote.
FAQs about Delix Therapeutics
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.